You are viewing the site in preview mode
Skip to main content
|
Subgroups
|
Appropriate EAMT group (n = 41)
|
Inappropriate EAMT group (n = 38)
|
|---|
|
Enlargement (n = 22)
|
Change (n = 9)
|
De-escalation (n = 7)
|
|---|
|
Bacteriologic documentation, n
|
28/41
|
18/22
|
9/9
|
7/7
|
|
NI location
|
|
VAP
|
22
|
11
|
2
|
4
|
|
Bacteraemia
|
3
|
7
|
3
|
2
|
|
CRI
|
2
|
5
|
3
|
0
|
|
CRB
|
1
|
1
|
0
|
1
|
|
UI
|
0
|
1
|
1
|
0
|
|
Isolates (n)
|
|
Acinetobacter B
|
14
|
6
|
0
|
0
|
|
Klebsiella pneumonia
|
6
|
4
|
0
|
0
|
|
Pseudomonas spp.
|
5
|
5
|
3
|
5
|
|
Enterobacter
|
2
|
4
|
1
|
0
|
|
E. coli
|
0
|
1
|
0
|
0
|
|
Staphylococcus
|
0
|
4
|
1
|
0
|
|
Enterococcus
|
0
|
3
|
1
|
0
|
|
Stenotrophomonas M
|
0
|
3
|
2
|
0
|
|
Burkholderiacepacia
|
1
|
0
|
0
|
0
|
|
Streptocoque spp.
|
0
|
0
|
0
|
2
|
|
Candida species
|
0
|
7
|
1
|
0
|
|
Antimicrobial adjustment
|
Imipenem/colistin
|
Imipenem/colistin/Glycopeptid (n = 8)
|
Other betalactam (for resistance to impenem) + tygecycline, aminoglycoside or quinolone (n = 6)
|
Piperacilline (n = 2)
|
|
Imipenem/colistin/antifungal (n = 7)
|
Glycopeptide ± aminoside (n = 2)
|
Ceftazidime (n = 3)
|
|
Imipenem/colistin/Tygecycline/aminglyosides (n = 3)
|
Antifungal (n = 1)
|
Cefotaxime (n = 2)
|
- EAMT, empiric antimicrobial therapy; NI, nosocomial infection; VAP, ventilator acquired pneumonia; CRI, catheter related infection; CRB, catheter related bacteraemia; UI, urinary infection
